Cizumab 400 (Bevacizumab) 400 mg/16 mL
Cizumab 400 (Bevacizumab 400 mg/16 ml) is a potent targeted therapy agent supplied in a larger vial size.
Manufacturer: Hetero Healthcare (India). It is a biosimilar to Avastin. The 400 mg vial is designed for convenient dosing in adult patients with higher body weight or dose requirements.
Mechanism of Action ("Anti-Angiogenesis"):
Bevacizumab works by neutralizing the Vascular Endothelial Growth Factor (VEGF). By blocking VEGF, it prevents the tumor from growing the new blood vessels it needs to survive. Essentially, it cuts off the tumor's supply line of oxygen and nutrients ("starving" the cancer).
✅ Key Benefit: Slows tumor progression and improves survival rates in metastatic cancers.
Indicated for advanced or metastatic cancers:
- 🎗 Colorectal Cancer: Metastatic carcinoma of the colon or rectum.
- 🫁 Non-Small Cell Lung Cancer (NSCLC): Non-squamous type.
- 🧠 Glioblastoma: Recurrent malignant brain tumors.
- 🥚 Ovarian Cancer: Advanced epithelial ovarian cancer.
- Renal Cell Carcinoma (Kidney Cancer).
Packaging: 16 ml Vial (Concentration 25 mg/ml = Total 400 mg).
⚠️ ADMINISTRATION GUIDELINES:
- 💉 IV Infusion: Must be diluted in 0.9% Sodium Chloride only. NEVER mix with Dextrose/Glucose solutions.
- ⏱ Dosing: Calculated based on body weight (mg/kg). Infusion time starts at 90 minutes and may be reduced if tolerated.
- 🔪 Surgery Warning: Discontinue use at least 28 days prior to elective surgery due to wound healing complications.
- Pregnancy and breastfeeding (teratogenic risk).
- History of hypertensive crisis.
- Recent hemoptysis (coughing up blood) or serious hemorrhage.
- Hypersensitivity to recombinant antibodies.
Potential side effects associated with VEGF inhibition:
- 🩸 Hemorrhage: Epistaxis (nosebleeds) is common; internal bleeding is a risk.
- ⚡ Hypertension: Elevated blood pressure requiring monitoring.
- 🩹 Wound Healing: Delayed healing of surgical incisions.
- Fatigue, proteinuria.
Similar products
What Customers Say
No reviews yet
Your review can be the first!